ORIENT-32 trial: what clinicians have said so far
A Study to Evaluate the Efficacy and Safety of Sintilimab in Combination With IBI305 (Anti-VEGF Monoclonal Antibody) Compared to Sorafenib as the First-Line Treatment for Advanced Hepatocellular Carcinoma.
- NCT03794440 ↗
- Unknown
- Innovent Biologics (Suzhou) Co. Ltd.
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on ORIENT-32 (sintilimab plus IBI305 in first-line unresectable hepatocellular carcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on ORIENT-32 so far
Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 podcast episodes, typically up to 13 once built | |
| 3 posts on X, typically up to 13 once built | |
| 1 YouTube video, typically up to 4 once built |
The trial
ClinicalTrials.gov- Official title
- A Randomized, Open-label,Multi-center Study to Evaluate the Efficacy and Safety of the Combination of Sintilimab and IBI305 Compared to Sorafenib in the First-Line Treatment of Patients With Advanced Hepatocellular Carcinoma. (ORIENT-32)
- Phase
- Phase 2/Phase 3
- Status
- Unknown
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Sintilimab; IBI305; Sorafenib
- Arms
- Sintilimab +IBI305 · Experimental
- Sorafenib · Active comparator
- Enrollment
- 595
- Primary outcomes
- Overall survival (OS)
- Progression-free survival (PFS)
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Start
- Feb 11, 2019
- Primary completion
- Dec 2022 (estimated)
- Results posted
- No
- Registry record
- NCT03794440 · updated Jan 22, 2021
Publications
linked from the registry- Ren Z, Xu J, Bai Y, Xu A, Cang S, Du C, Li Q, Lu Y, Chen Y, Guo Y, Chen Z, Liu B, Jia W, Wu J, Wang J, Shao G, Zhang B, Shan Y, Meng Z, Wu J, Gu S, Yang W, Liu C, Shi X, Gao Z, Yin T, Cui J, Huang M, Xing B, Mao Y, Teng G, Qin Y, Wang J, Xia F, Yin G, Yang Y, Chen M, Wang Y, Zhou H, Fan J; ORIENT-32 study group. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study. Lancet Oncol. 2021 Jul;22(7):977-990. doi: 10.1016/S1470-2045(21)00252-7. Epub 2021 Jun 15. PubMed 34143971